Rituximab and Intravenous Immunoglobulin (IVIG) for Desensitization in Renal Transplantation

Part of paid clinical trials in Los Angeles, California.

Sponsor
Cedars-Sinai Medical Center
Study ID
NCT00642655
Phase
PHASE1/PHASE2
Status
Completed

Conditions

  • Kidney Transplant

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • IVIG and Rituximab — DRUG
    IVIG 2gm/kg given intravenously on day#0 and day#30 Rituximab 1gm given intravenously on day#7 and day#22

Study Details

The purpose of this study is to examine the safety and efficacy of IVIG in combination with Rituximab to lower the level of HLA-sensitive antibodies and block their ability to attack a transplanted organ in patients who are highly HLA-sensitized and are awaiting transplantation.

Key Dates

Start date
Sep 30, 2005
Status verified
Mar 2008
Primary completion
May 31, 2007
Completion
May 31, 2007

Study Design

Enrollment
20 participants (actual)
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Primary Outcome Measure

Success of transplantation [ Time Frame: 12 months ]

Locations (1)

FacilityCityStateZIPSite coordinators
8700 Beverly Blvd.Los AngelesCalifornia90048-

Find similar trials in Los Angeles, CA

By research site
8700 Beverly Blvd.· Los Angeles, CA

Related Studies